scholarly journals Evaluation of urinary and serum level of chemokine (C‐C motif) ligand 2 as a potential biomarker in canine urothelial tumours

2018 ◽  
Vol 17 (1) ◽  
pp. 11-20 ◽  
Author(s):  
N. Shimizu ◽  
A. Hamaide ◽  
M. Dourcy ◽  
S. Noël ◽  
C. Clercx ◽  
...  
Keyword(s):  
Serum Level ◽  
Potential Biomarker ◽  
Urothelial Tumours

scholarly journals Serum Level of Antibodies (IgG, IgM) Against Benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA Adducts in Children Dermatologically Exposed to Coal Tar

2017 ◽  
Vol 60 (1) ◽  
pp. 27-31 ◽  
Author(s):  
Pavel Borský ◽  
Ctirad Andrýs ◽  
Jan Krejsek ◽  
Květoslava Hamáková ◽  
Jan Kremláček ◽  
...  
Keyword(s):  
Immune Response ◽  
Polycyclic Aromatic Hydrocarbons ◽  
Serum Level ◽  
Dna Adducts ◽  
Aromatic Hydrocarbons ◽  
Coal Tar ◽  
Reactive Metabolite ◽  
Potential Biomarker ◽  
Polycyclic Aromatic ◽  
Dermal Application

Crude coal tar (CCT) contains polycyclic aromatic hydrocarbons (PAHs). Benzo[a]pyrene (BaP) is metabolized into a highly reactive metabolite benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE) that is able to bind to DNA and creates BPDE-DNA adducts. Adducted DNA becomes immunogenic and induces immune response by production of antibodies against BPDE-DNA adducts (Ab-BPDE-DNA). Circulating Ab-BPDE-DNA was proposed as potential biomarker of genotoxic exposure to BaP (PAHs). Goeckerman therapy (GT) of psoriasis uses dermal application of CCT ointment (PAHs). In presented study (children with psoriasis treated by GT; n = 19) the therapy significantly increased the level of Ab-BPDE-DNA (EI = 0.29/0.19–0.34 vs. 0.31/0.25–0.40; median/lower–upper quartile; p < 0.01). The results support the idea of Ab-BPDE-DNA level as a possible tentative indicator of exposure, effects and susceptibility of the organism to the exposure of BaP (PAHs).

scholarly journals Evaluation of Interleukin-2 to Detect Active and Latent Tuberculosis among Household Contacts of Pulmonary Tuberculosis Cases

2021 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Azadeh Jafrasteh ◽  
Abdollah Karimi ◽  
Seyedeh Mahsan Hoseinialfatemi ◽  
Leila Azimi ◽  
Payam Tabarsi ◽  
...  
Keyword(s):  
Serum Level ◽  
Active Form ◽  
Interleukin 2 ◽  
Clinical Manifestations ◽  
Latent Tuberculosis ◽  
Tuberculosis Infection ◽  
Mycobacterium Tuberculosis Infection ◽  
Laboratory Findings ◽  
Household Contacts ◽  
Potential Biomarker

Background: The interferon-gamma release assays (IGRAs) are the most important diagnostic approach to Mycobacterium tuberculosis infection diagnosis. However, they cannot discriminate between latent tuberculosis infection (LTBI) and active tuberculosis (TB). Some recent studies suggested that interleukin-2 (IL-2) response to M. tuberculosis could be utilized as a potential biomarker to discriminate active disease from LTBI. Objectives: The current study aimed at evaluating the potential role of IL-2 to detect both active TB and LTBI among household contacts of patients with pulmonary TB in two TB-endemic regions of Iran. Methods: A total of 650 household contacts of patients with TB were invited to participate in the current study. All subjects were diagnosed on extensive clinical evaluation of active TB and LTBI based on clinical manifestations and laboratory findings. The IGRA test was performed using QuantiFERON®-TB Gold Plus. The serum level of IL-2 was measured using the ELISA Development Kit. Results: A total of 237 household contacts entered the final analysis, including 132 patients with LTBI and three with active TB. In addition, 14 subjects were included as TB controls and 102 as TB-uninfected controls. The serum level of IL-2 was significantly higher in active TB and LTBI patients than TB-uninfected controls. The ROC curve was plotted between active TB and LTBI, revealing that the cutoff point of 25.5 pg/mL identifies the active form with 88.24% sensitivity and 36.36% specificity. Conclusions: The current study indicated that the IL-2 assay could not discriminate between active TB and LTBI with acceptable sensitivity.

scholarly journals Serum Level and Tumor Tissue Expression of Ribonucleotide-Diphosphate Reductase Subunit M2 B: A Potential Biomarker for Colorectal Cancer

2021 ◽  
Author(s):  
Naser Mobarra ◽  
Hanieh Gholamalizadeh ◽  
Kaed A. Abdulhussein ◽  
Fatemeh Taheri Asl ◽  
Mobina Sadat Mirvahabi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Serum Level ◽  
Tumor Metastasis ◽  
Tumor Tissue ◽  
Tumor Staging ◽  
Tissue Expression ◽  
Control Group ◽  
Potential Biomarker ◽  
The Mean ◽  
First Time

Abstract Background: This study aimed to investigate whether serum level and tissue expression of Ribonucleotide-diphosphate Reductase subunit M2 B (RRM2B) could be recognized as reliable biomarkers for colorectal cancer (CRC) progression and metastasis.Methods and Results: This descriptive-analytic cohort study was conducted on 50 newly diagnosed CRC patients (stage II, III) and 50 healthy individuals. The new cases had not received any therapeutic intervention and underwent surgery immediately after the initial diagnosis. Tumorous tissues and marginal healthy tissues as control were excised to determine the mRNA tissue expression of RRM2B by Real-Time PCR. Serum RRM2B protein was measured using an ELISA method once in the control group and in the patients before, one, and three months after surgery. The tumor metastasis node (TMN) classification system and liver metastasis were evaluated in CRC patients. The mean RRM2B gene expression in tumor tissue was 51% lower than adjacent normal tissue (P < 0.001). We did not find a significant relationship between serum level of RRM2B and tumor staging and metastasis in patients before surgery (P = 0.373, P = 0.189), one month after surgery (P = 0.960, P = 0.088), and three months after surgery (P = 0.407, P = 0.724). RRM2B expression in tumor tissue was not associated with tumor staging and metastasis (P = 0.254, P = 0.721)Conclusion: Our study indicates the first time evidence that RRM2B may serve as a potential biomarker for CRC.

scholarly journals Serum AFU, 5’-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis

Open Medicine ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. 354-358 ◽  
Author(s):  
Zhu Junna ◽  
Chen Gongde ◽  
Xu Jinying ◽  
Zhou Xiu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Serum Level ◽  
Roc Curve ◽  
Diagnostic Sensitivity ◽  
Primary Hepatocellular Carcinoma ◽  
Control Group ◽  
Healthy Controls ◽  
Clinical Value ◽  
Potential Biomarker ◽  
Healthy Control

AbstractTo evaluate the clinical value of serum α-L-fucosidase (AFU), 5’-nucleotidase (5’-NT) and alpha fetoprotein (AFP) as biomarkers for primary hepatocellular carcinoma (PHC) diagnosis. Methods: Thirty six primary hepatocellular carcinoma (PHC) patients and 36 healthy controls were recruited in this study from February 2014 to January 2016 in the Second People’s Hospital of Tianjin. The serum level of AFU, 5’-NT and AFP were examined and compared between the two groups. The diagnostic sensitivity, specificity area under the receiver operating characteristic (ROC) curve were calculated by STATA11.0 software. Results: The serum level of AFU, 5’-NT, AFP were 30.87±10.43(U/L), 5.58±3.89(U/L), 233.60±226.60 (μg/L) respectively for primary hepatocellular carcinoma group and 19.96±6.73 (U/L), 1.87±0.84 (U/L), 16.64±14.17 (μg/L) for healthy control groups. The serum level of AFU, 5’-NT and AFP in primary hepatocellular carcinoma group were significant higher than those of healthy control group (P<0.001). The diagnostic sensitivity and specificity were 0.78 (95%CI:l0.61-0.90), 0.64 (95%CI:0.46-0.79) for serum AFU, 0.75(95%CI:0.58-0.88), 0.72(95%CI:0.55- 0.86) for serum 5’-NT and 0.72 (95%CI:0.55-0.86), 0.92 (95%CI:0.78-0.98) for serum AFP respectively. The AUC under the ROC curve were 0.80 (0.69-0.90), 0.80 (0.69-0.91) and 0.87 (0.780-0.96) for serum AFU, 5’-NT and AFP respectively. Positive correlation between AFU and 5’-NT (rpearson=0.63, P<0.05), AFU and AFP (rpearson=0.49, P<0.05), 5’-NT and AFP(rpearson=0.44, P<0.05) were found in the primary hepatocellular carcinoma patients. Conclusion: Serum AFU, 5’-NT and AFP were higher in PHC patients than those of healthy controls. The difference between PHC patients and healthy controls made serum AFU, 5’-NT and AFP potential biomarker for PHC diagnosis.

scholarly journals Serum level of nerve growth factor is a potential biomarker of conversion to bipolar disorder in women with major depressive disorder

2019 ◽  
Vol 73 (9) ◽  
pp. 590-593 ◽  
Author(s):  
Fernanda Pedrotti Moreira ◽  
Taiane C. Cardoso ◽  
Thaíse C. Mondin ◽  
Carolina D. Wiener ◽  
Luciano D. de Mattos Souza ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Major Depressive Disorder ◽  
Nerve Growth Factor ◽  
Growth Factor ◽  
Serum Level ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Nerve Growth ◽  
Potential Biomarker

Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma

2017 ◽  
Vol 35 (5) ◽  
pp. 279-285 ◽  
Author(s):  
Dong Dong ◽  
Li Jia ◽  
Yunli Zhou ◽  
Li Ren ◽  
Juan Li ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Serum Level ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Potential Biomarker

scholarly journals Serum sTREM-1, PCT, CRP, Lac as biomarkers for death risk within 28 days in patients with severe sepsis

2018 ◽  
Vol 13 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Lefeng Zhang ◽  
Xiaohong Zhang
Keyword(s):  
Severe Sepsis ◽  
Serum Level ◽  
Myeloid Cell ◽  
Serum Levels ◽  
Survival Group ◽  
Death Risk ◽  
Reactive Protein ◽  
Potential Biomarker ◽  
Sensitivity Specificity ◽  
Death Group

AbstractThis study was undertaken to evaluate the clinical efficacy of serum soluble triggering receptors expressed by myeloid cell-1 (sTREM-1), procalcitonin (PCT), C-reactive protein (CRP) and lactic acid (Lac) as biomarkers for death risk within 28 days in patients with severe sepsis. Fifty-one cases of severe sepsis from the department of ICU in Lishui People’s Hospital from May 2013 to February 2017 were retrospectively analyzed. These cases were divided into survival (n=39) and death (n=12) groups based on the outcome within 28 days of treatment. Serum levels of sTREM-1, PCT, CRP and Lac were measured on the day of admission and compared between the survival and death groups. And the death prediction value within 28 days were evaluated according to serum sTREM-1, PCT, CRP and Lac. The serum level of TREM-1 and Lac were 128.70±46.10 pg/mL, 7.02±1.56 mmol/L for the death group and 83.69±26.57 pg/mL 4.44±0.45 mmol/L for survival group. The serum levels of sTREM-1 and Lac in death group were significantly higher than those of survival group (p<0.05). However, the serum PCT and CRP between the survival and death group were not statistically different (p>0.05). The death prediction sensitivity, specificity and AUC within 28 days were high for serum sTREM-1 (75.00%, 77.78%, 0.79) and APACHEII (74.89%, 84.62%, 0.84). However, the prediction value of serum level PCT, CRP and Lac were relatively low. A significant positive correlation was found between serum sTREM-1 and APACHEII score rpearson =0.54, (p<0.001). However, no such correlation was observed between serum CRP, Lac and APACHEII scores (p>0.05).ConclusionSerum sTREM-1 was significantly elevated in sepsis patients who died within 28 days of admission, suggesting that this test could be a potential biomarker for severe sepsis patients, and also be used for prognostic evaluation.

The miR-21 potential of serving as a biomarker for liver diseases in clinical practice

2020 ◽  
Vol 48 (5) ◽  
pp. 2295-2305
Author(s):  
Jiawei Zhang ◽  
Dandan Li ◽  
Rui Zhang ◽  
Peng Gao ◽  
Rongxue Peng ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Diseases ◽  
Hepatic Disease ◽  
Noninvasive Detection ◽  
Diagnosis And Prognosis ◽  
Expected Performance ◽  
Potential Biomarker ◽  
Disease Condition ◽  
Complex Regulatory Network

The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.

Sign in / Sign up

Export Citation Format

Share Document